Title:
PROTEINS SPECIFIC FOR CD137
Document Type and Number:
Japanese Patent JP2022177231
Kind Code:
A
Abstract:
To provide human lipocalin muteins used for the treatment or prevention of diseases such as cancer, infectious diseases, and autoimmune diseases, and compositions.SOLUTION: The present disclosure provides a CD137-binding lipocalin mutein comprising at least one mutated amino acid residue at a specific position of a linear polypeptide sequence of mature human tear lipocalin, a nucleic acid molecule encoding the lipocalin mutein, a method for therapeutic and/or diagnostic use of the lipocalin mutein, as well as a composition comprising the lipocalin mutein.SELECTED DRAWING: None
Inventors:
Hinner Marlon
Rote Christine
Olville Shane
Area Shudolfer Andrea
Bell Aiba Rashida Shiham
Rote Christine
Olville Shane
Area Shudolfer Andrea
Bell Aiba Rashida Shiham
Application Number:
JP2022152103A
Publication Date:
November 30, 2022
Filing Date:
September 26, 2022
Export Citation:
Assignee:
Pieris Pharmaceuticals Gem Beher
International Classes:
C12N15/12; C07K14/47; C07K16/00; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N5/0783; C12N5/10; C12N15/13; C12N15/62; C12P21/02
Attorney, Agent or Firm:
Shimizu Hatsushi
Masao Haruna
Hirotaka Yamaguchi
Shun Jinbe
Ryuichi Inoue
Toshimitsu Sato
Koichi Niimi
Tomohiko Kobayashi
Hideki Kodera
Masato Ozeki
Kazuya Kawamoto
Masao Haruna
Hirotaka Yamaguchi
Shun Jinbe
Ryuichi Inoue
Toshimitsu Sato
Koichi Niimi
Tomohiko Kobayashi
Hideki Kodera
Masato Ozeki
Kazuya Kawamoto